Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Lumakras study was called into question A Phase 3 trial that was meant to confirm the data that won Amgens Lumakras (sotorasib) expedited approval didnt pass muster with a panel of FDA advisers
For additional information on statistical analyses, please refer to the figure legends
Full results are usually visible after the recommended series of treatments
Clin Interv Aging (2015) 10:54960
US$ 22.94
US$ 21.89
US$ 25.08
US$ 24.51
US$ 22.63
US$ 20.77
US$ 21.71
US$ 26.07
US$ 24.58
